Sanofi and Re­gen­eron's block­buster Dupix­ent re­ject­ed by FDA for chron­ic hives con­di­tion

US reg­u­la­tors want to see more ef­fi­ca­cy da­ta be­fore they con­sid­er ap­prov­ing Sanofi and Re­gen­eron’s Dupix­ent in a skin con­di­tion char­ac­ter­ized by chron­ic hives, Sanofi …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER